

ULTOMIRIS[®] REMS


ULTOMIRIS is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS)

- Healthcare providers (HCPs) must be specifically certified to prescribe ULTOMIRIS
- Certification consists of review of REMS educational materials and enrollment in the ULTOMIRIS REMS program
- Under the ULTOMIRIS REMS, prescribers must enroll in the program
- Enrollment in the ULTOMIRIS REMS program and additional information are available by telephone: 1-888-765-4747 or at www.ultomirisrems.com

The purpose of the ULTOMIRIS REMS is to mitigate the occurrence and morbidity associated with meningococcal infections by informing HCPs and patients about the:

- Increased risk of meningococcal infections with ULTOMIRIS
- Early signs of invasive meningococcal infections
- Need for immediate medical evaluation of signs and symptoms consistent with possible meningococcal infections

For more information
or to enroll, visit
ULTOMIRISrems.com
or scan the QR code




ULTOMIRIS[®]
(ravulizumab-cwvz)
injection for intravenous use
300 mg/3 mL vial

For more information or to enroll, visit:

www.ULTOMIRISrems.com

or scan the QR code below:



ULTOMIRIS, the ULTOMIRIS logo, and the ALEXION logo are registered trademarks of Alexion Pharmaceuticals, Inc.

© 2022, Alexion Pharmaceuticals, Inc. All rights reserved. US/ULT-g/0124 04/22


AstraZeneca Rare Disease